Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Trial Profile

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosfomycin (Primary) ; Piperacillin/tazobactam
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEUS
  • Sponsors Zavante Therapeutics
  • Most Recent Events

    • 29 Aug 2022 Results of an analysis assessed the Desirability of outcome ranking (DOOR) approach application to Improving traditional registrational trial endpoints applied to three registrational drug trials (ZEUS, APEKS-cUTI, and DORI-05) published in the Clinical Infectious Diseases
    • 05 Apr 2021 According to a Nabriva Therapeutics media release, this extension provides the Agency adequate time to assess the application of the recently issued guidance entitled "Remote Interactive Evaluations for Oversight of Drug Facilities During COVID-19" to the CONTEPO re-submission.
    • 05 Apr 2021 According to a Nabriva Therapeutics media release, the Food and Drug Administration (FDA) granted Nabriva an extension for the re-submission of the New Drug Application for CONTEPO with the FDA to June 19, 2022 due to the ongoing COVID-related travel restrictions that have impacted the Agency's ability to conduct onsite inspections of foreign manufacturing facilities.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top